Chemokine analogues show suitable stability for development as microbicides

Journal of Acquired Immune Deficiency Syndromes

Volumn 49, Issue 5, 2008, Pages 472-476

  Cerini, Fabrice ^a   Landay, Alan ^b   Gichinga, Carolyne ^b   Lederman, Michael M ^c   Flyckt, Rebecca ^d   Starte, David ^d   Offord, Robin E ^e   Le Gal, François ^f   Hanley, Oliver ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b RUSH UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e Mintaka Foundation for Medical Research   (Switzerland)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

CCR5; Chemokine; HW AIDS; Microbicide; Prevention; Stability

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; MICROBICIDE; PSC RANTES; RANTES 5P12; RANTES 6P4; UNCLASSIFIED DRUG; 5P12 RANTES; 5P12-RANTES; 6P4 RANTES; 6P4-RANTES; BETA CHEMOKINE; RANTES; RANTES, N(ALPHA) (N NONANOYL) DESSER(1) (THIOPROLINE(2),CYCLOHEXYLGLYCINE(3)); RANTES, N(ALPHA)-(N-NONANOYL)-DESSER(1)-(THIOPROLINE(2),CYCLOHEXYLGLYCINE(3))-;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CELL FUSION; CONTROLLED STUDY; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN TISSUE; IC 50; MALE; PH; PRIORITY JOURNAL; SEMEN ANALYSIS; STORAGE TEMPERATURE; UTERINE CERVIX; UTERINE CERVIX CYTOLOGY; VAGINA; VAGINAL LAVAGE; VIRUS ENTRY; VIRUS INHIBITION; CHEMISTRY; DOSE RESPONSE; HEAT; HELA CELL; SPERM;

ANTI-HIV AGENTS; CHEMOKINE CCL5; CHEMOKINES, CC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; FEMALE; HELA CELLS; HOT TEMPERATURE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; SEMEN; VAGINA;

EID: 60749109098     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31818c953f     Document Type: Article

References (25)

1. UN AIDS/World Health Organisation. AIDS Epidemie Update. Geneva, Switzerland: UN AIDS/World Health Organisation; 2007.
2. HIV vaccine failure prompts Merck to halt trial. Nature. 2007;449:390.
3. Klasse PJ, Shattock RJ, Moore JP. Which topical microbicides for blocking HIV-1 transmission will work in the real world? PLoS Med. 2006;3(9).
4. Lederman MM, Offord RE, Hartley O. Microbicides and other topical strategies to prevent vaginal transmission of HIV Nat Rev Immunol. 2006; 6:371-382.
5. Bolognesi N. AIDS gel's failure calls prevention approach into question. Nat Med. 2007;13:230.
6. Cohen J. AIDS research. Microbicide fails to protect against HIV Science. 2008;319:1026-1027.
7. Hillier SL, Moench T, Shattock R, et al. In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr. 2005;39:1-8.
8. Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol. 2003;1:25-34.
9. Cocchi F, DeVico AL, Garzino DA, et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV- suppressive factors produced by CD8+ T cells [see comments]. Science. 1995;270: 1811-1815.
10. Simmons G, Clapham PR, Picard L, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science. 1997;276:276-279.
11. Polo S, Nardese V, Santis CD, et al. Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation. Eur J Immunol. 2000;30: 3190-3198.
12. Townson JR, Graham GJ, Landau NR, et al. Aminooxypentane addition to the chemokine macrophage inflammatory protein-1 alpha P increases receptor affinities and HIV inhibition. J Biol Chem. 2000;275: 39254-39261.
13. Hartley O, Dorgham K, Perez-Bercoff D, et al. Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines. J Virol. 2003;77:6637-6644.
14. Hartley O, Gaertner H, Wilken J, et al. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors. Proc Natl Acad Sci USA. 2004;101:16460-16465.
15. Gaertner H, Lebeau O, Borlat I, et al. Highly potent HIV inhibition: engineering a key anti-HIV structure from PSC-RANTES into MIPl{beta}/CCL4. Protein Eng Des Sci. 2008;21:65-72.
16. Gaertner H, Offord R, Botti P, et al. Semisynthetic analogues of PSCRANTES, a potent anti-HIV protein. Bioconjug Chem. 2008;19:480-489.
17. Lederman MM, Veazey RS, Offord R, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science. 2004;306:485-487.
18. Moore JP. Topical microbicides become topical. N Engl J Med. 2005;352: 298-300.
19. Schafer T, Borchert TW, Nielsen VS, et al. Industrial enzymes. Adv Biochem Eng Biotechnol. 2007;105:59-131.
20. Pleskoff O, Treboute C, Brelot A, et al. Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry [see comments]. Science. 1997;276:1874-1878.
21. Jouannet P, Ducot B, Feneux D, et al. Male factors and the likelihood of pregnancy in infertile couples. I. Study of sperm characteristics. Int J Androl. 1988;11:379-394.
22. World Health Organisation. WHO Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction. 1999: 60-61.
23. Eckert LO. Clinical practice, acute vulvovaginitis. N Engl J Med. 2006; 355:1244-1252.
24. Koren E, Lukac J. Mechanism of liquefaction of the human ejaculate. I. Changes of the ejaculate proteins. J Reprod Fertil. 1979;56:493-499.
25. World Health Organisation. WHO Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction. 1999:6.